# Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/par-21-274-cancer-target-discovery-and-development-ctd2-u01-clinical/  
Official notice: https://www.grants.gov/search-results-detail/334676

> National Institutes of Health offered grants of up to $750,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 12 awards worth $12.0 million in total. Applications closed on October 6, 2022.

| Field | Value |
|---|---|
| Opportunity number | PAR-21-274 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | October 6, 2022 |
| Award ceiling | $750,000 |
| Award floor | not stated |
| Expected awards | 12 |
| Total funding | $12.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.395, 93.396 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support the program "Cancer Target Discovery and Development (CTD2, pronounced cee-tee-dee-squared). CTD2 is focused on efforts that advance cancer research by bridging the knowledge gap between the large volumes of comprehensive molecular characterizations of many cancer types and studies of the underlying etiology of cancer development, progression, and/or metastasis. The primary purpose of CTD2 is to advance the following areas: Improving the understanding of how mutations in cancer-associated genes affect the protein activity (e.g., gain-of-function, loss-of-function, or neomorphic function) within the cellular pathway(s) they are part of and the cellular changes that result within the context of various tumors and the microenvironment; Identifying new molecular targets with the goal to understand their wiring mechanisms and how overcome innate and/or acquired resistance to therapies, particularly clinical resistance related to inter- and intra- tumor heterogeneity; and Developing efficient strategies to identify appropriate multiple targets and optimal combination of perturbagens (chemical or biological; immunotherapeutics being a prime example of the latter) with the potential to eliminate all cancer cells, despite their clonal heterogeneity and their surrounding microenvironment.

## Questions people ask

### Is PAR-21-274 still open?

No. It closed on October 6, 2022.

### Who can apply for Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Cancer Target Discovery and Development (CTD2) (U01 Clinical Trial Not Allowed)?

Closed October 6, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $750,000 each. About $12.0 million in total across about 12 awards.

### Who has been funded under PAR-21-274?

NIH RePORTER lists 7 projects funded under PAR-21-274 in fiscal 2022 to 2026, at 7 institutions. The most were at Fred Hutchinson Cancer Center, Columbia University Health Sciences, Oregon Health & Science University.

### Who has won Cancer Treatment Research grants before?

The largest recipients over five fiscal years were The Univeristy of Texas M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, Inc., Icahn School of Medicine at Mount Sinai. The program made 3,622 awards worth $5.6 billion in that time.